Skip to main content
Sarah Rutherford, MD, Oncology, New York, NY

SarahRutherfordMD

Oncology • New York, NY

Hematologic Oncology

Physician

Request Appointment

Overview of Dr. Rutherford

Dr. Sarah Rutherford is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from University of Virginia School of Medicine and has been in practice 8 years. She is one of 375 doctors at New York-Presbyterian Hospital and one of 118 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 30 publications and over 250 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2009 - 2012
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 2009

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2011 - 2026
  • PA State Medical License
    PA State Medical License 2009 - 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Extracellular Vesicles in DLBCL Provide Abundant Clues to Aberrant Transcriptional Programming and Genomic Alterations  
    Sarah C Rutherford, Ashish Saxena, Rita Shaknovich, Blood

Abstracts/Posters

  • Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
    Sarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
    Sarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset
    Sarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Press Mentions

  • Major Eligibility Expansion Brings Moment of Truth for COVID Vaccines: Will Florida’s Young People Want Them?
    Major Eligibility Expansion Brings Moment of Truth for COVID Vaccines: Will Florida’s Young People Want Them?April 2nd, 2021
  • AI Therapeutics Announces That a Common LAM-002 Mechanism in Cancer and Neurodegenerative Diseases Shows Antitumor Activity in the Clinic and Hope for ALS
    AI Therapeutics Announces That a Common LAM-002 Mechanism in Cancer and Neurodegenerative Diseases Shows Antitumor Activity in the Clinic and Hope for ALSJanuary 16th, 2020
  • LAM Therapeutics Announces Progress of Its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma
    LAM Therapeutics Announces Progress of Its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in LymphomaNovember 30th, 2017
  • Join now to see all

Dr. Sarah Rutherford, Dr. Sarah Rutherford, MD, Dr. S Rutherford